What Evidence Can and Cannot Show About Reglan and Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one has developed uncontrollable facial or body movements after taking Reglan, you may be wondering whether these symptoms point to tardive dyskinesia. Differentiating between subjective symptoms and a formal diagnosis requires specific medical evidence. Over decades of clinical research, the medical community has established clear criteria for diagnosing this condition, yet many patients remain unaware of what that evidence can and cannot show. This page explains the distinction and what it means for your situation.

Find Out If You Qualify for Compensation →

Medical Evidence: Reglan and Tardive Dyskinesia Risk

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information explicitly limits use for gastroesophageal reflux to 4 to 12 weeks and states that Reglan has not been shown to be safe or effective for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, recommends routine monitoring for signs and symptoms of tardive dyskinesia (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia (TD) is a syndrome of potentially irreversible and disfiguring involuntary movements, typically involving the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition is caused by metoclopramide, the active ingredient in Reglan, and the risk of developing TD increases with longer duration of treatment and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-required boxed warning states that Reglan can cause TD, a potentially irreversible serious movement disorder, and that the drug is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also instructs prescribers to use Reglan for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The label notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical concern because it can allow TD to progress unrecognized while the patient continues taking the drug. Clinical presentation of TD typically includes repetitive, involuntary movements such as lip smacking, tongue protrusion, grimacing, and rapid blinking. In more advanced cases, movements may involve the trunk and extremities, including choreoathetoid motions. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide. The condition can be irreversible even after discontinuation of the drug, underscoring the importance of early detection.

Statute of Limitations for Reglan Claims in California

For patients in California who have developed TD after taking Reglan, several legal considerations arise. The statute of limitations for personal injury claims in California is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For medical malpractice claims, the statute is typically one year from discovery or three years from the date of injury, whichever occurs first. However, these timelines can be complex, especially when the injury is latent, as TD may not become apparent until months or years after exposure. The timeline between exposure to Reglan and documented harm is variable; TD can develop after weeks to years of use, and the risk increases with cumulative exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delayed onset can complicate the determination of when the statute of limitations begins to run. Adequacy of warnings is a central issue in potential litigation. The FDA-approved label includes a boxed warning about TD, but questions may arise about whether prescribers and patients received sufficient information about the risk, especially given that Reglan is sometimes used off-label or for longer durations than recommended. The label explicitly states that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may have been prescribed Reglan for extended periods without adequate monitoring or informed consent. Attorney-related considerations for affected patients include the need to document the duration and dosage of Reglan use, the onset and progression of TD symptoms, and any medical records that show whether the prescribing physician discussed the risk of TD. Patients should also preserve all medication bottles and pharmacy records. Consulting with an attorney experienced in pharmaceutical litigation is advisable to evaluate the specific facts of the case, including whether the statute of limitations has been met and whether the manufacturer or prescriber failed to provide adequate warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or discovery. For medical malpractice, it is typically one year from discovery or three years from injury, whichever comes first. Because tardive dyskinesia may develop months or years after Reglan use, the discovery rule can affect these deadlines. Consulting an attorney is essential to determine the applicable deadline based on your specific circumstances.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) blocks dopamine D2 receptors in the brain, which can lead to dopamine receptor supersensitivity and involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses. The FDA label includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Reglan Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.